Black Diamond Therapeutics, Inc. (BDTX): Total Assets
$143.01M
As of 2025-12-31
$125.03M
As of 2026-06-30
-2.9%
3-year compound annual growth
-15.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $143.01M | +16.6% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $122.64M | -22.7% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $158.57M | +1.5% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $156.25M | -36.9% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $247.68M | -24.9% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $329.67M | +108.3% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $158.29M | +205.4% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $51.83M | n/a | 2020-03-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
Compare BDTX, VIR, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗